Oxford Ovarian Cancer Predict Chemotherapy Response 01

• Conditions: Ovarian Cancer

• Registration Number: NCT01770535
• Lead Sponsor: University of Oxford

Brief Summary

The purpose of the study is to understand why there are differences between individuals in the way they respond to paclitaxel chemotherapy.

Detailed Description

While paclitaxel is very effective in killing cancer cells in a proportion of patients, some patients don't respond to this treatment. As with any chemotherapy, paclitaxel is associated with unpleasant side effects. We are doing this study to try and understand what is happening in cancer cells in different individuals after paclitaxel treatment that make them respond differently to the same treatment. We hope that this study will enable us to develop a method to identify women who are suitable for this form of treatment. We also want to understand why some cancer cells don't get killed with paclitaxel. This information will help us to select treatment to suit an individual patient, and thus improve the outcome of treatment and avoid giving treatment that will not benefit the patient.

Study Timeline

• Study Start: 2012-11
• Status Verified: 2013-01
• Study First Submitted: 2013-01-15
• Study First Submitted QC: 2013-01-15
• Last Update Submitted: 2013-01-15
• Study First Posted: 2013-01-17
• Last Update Posted: 2013-01-17
• Primary Completion: 2014-12
• Study Completion: 2015-06

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: Female
• Target Recruitment: 35

Inclusion Criteria

• Female ≥ 18 years of age
• Newly diagnosed and histology confirmed primary high grade serous ovarian cancer, high grade serous fallopian tube cancer and primary peritoneal carcinoma.
• Radiological and laparoscopic confirmation of FIGO stage 3C or 4 ovarian cancer.
• Radiological evidence of omental or peritoneal deposits that are accessible for radiology-guided biopsy.
• At least one lesion on CT scan measuring at least 2 cm in maximum diameter performed in the past 31 days. Slightly older scans may be accepted at the discretion of the CI providing the results are considered to remain clinically relevant.
• Eastern Cooperative Oncology Group (ECOG) performance score of 0-2
• Life expectancy of at least 6 months.
• The patient is willing and able to provide written informed consent and comply with the protocol for the duration of the study, and scheduled visits and examinations.
• Acceptable haematological and biochemical indices

Exclusion Criteria

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Correlation between βIII tubulin expression and Mitotic Index (MI) following single agent paclitaxel treatment	Before and 24-hours after paclitaxel treatment	Correlation between βIII tubulin expression and Mitotic Index (MI) before and after single agent paclitaxel treatment to determine whether overexpression of βIII tubulin is associated with Paclitaxel resistance

Secondary Outcome Measures

Name	Time	Method
Correlation between mitotic index and the magnitude of CA125 response	three weeks after paclitaxel treatment	Correlation between mitotic index and the magnitude of CA125 response will be analysed to investigate whether post-paclitaxel mitotic index is a determinant of clinical response in ovarian cancer

Trial Locations

Locations (1)

Churchill Hospital; 🇬🇧 Oxford, United Kingdom